VCG
SUPN icon

Vantage Consulting Group’s Supernus Pharmaceuticals SUPN Stock Holding History

Vantage Consulting Group’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,014
Closed -$26K – 1386
2020
Q4 		$26K Buy
+1,014
New +$21.8K ﹤0.01% 763

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Vantage Consulting Group's SUPN Position: Q1 2021 in Review

Vantage Consulting Group sold out of Supernus Pharmaceuticals (SUPN) in Q1 2021, closing a stake of 1,014 shares — an estimated $26K sold.

Vantage Consulting Group first reported a position in SUPN in Q4 2020 and held it in 1 quarter. The position peaked at $26K in Q4 2020. 224 funds tracked by Wall St. Rank hold SUPN as of Q1 2021.

  • Vantage Consulting Group reported no remaining Supernus Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Vantage Consulting Group sold 1,014 Supernus Pharmaceuticals shares in Q1 2021, an estimated $26K.
  • Vantage Consulting Group first reported a position in Supernus Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Vantage Consulting Group's Supernus Pharmaceuticals position peaked at $26K in Q4 2020.
  • 224 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.